Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended versus routine aprepitant scheduling for prevention of cisplatin-induced nausea and vomiting in lung cancer
ChiCTR-IPR-15005933Phase 4Not yet recruiting
- Sponsor
- Cancer Center, West China Hospital, Sichuan University
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV) (3 arms), sponsored by Cancer Center, West China Hospital, Sichuan University. Primary endpoints: Complete response rate, Frequency of rescue antiemetic use and 2 more. Planned start Jan 2015; status: not yet recruiting.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR-IPR-15005933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15005933.